ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Monday, November 13, 2023

9:00AM-11:00AM: Abstract Number: 1246

Assessment and Outcomes of 63 Cases of Juvenile Dermatomyositis-Associated Calcinosis

(1221–1255) Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1567

Assessment of the Extent and Accrual of Damage in Takayasu’s Arteritis

(1554–1578) Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

9:00AM-11:00AM: Abstract Number: 1065

Association Between COVID-19 and Disease-Modifying Antirheumatic Drugs

(1052–1081) Immunological Complications of Medical Therapy Poster

9:00AM-11:00AM: Abstract Number: 0983

Association Between Disease-modifying Anti-rheumatic Drugs and Short-term Outcomes of Dengue: A Population-based, Cohort Study

(0965–0992) Epidemiology & Public Health Poster II

9:00AM-11:00AM: Abstract Number: 0992

Association Between Metabolic Syndrome and the Presence of Enthesophytes on Musculoskeletal Ultrasound Compared to Joint X-ray

(0965–0992) Epidemiology & Public Health Poster II

9:00AM-11:00AM: Abstract Number: 1137

Association Between Nailfold Videocapillaroscopy Findings and sKL-6 Levels in Patients with Idiopathic Inflammatory Myopathies–Related Interstitial Lung Disease

(1124–1154) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

9:00AM-11:00AM: Abstract Number: 0908

Association of Biologic Sex with Glycosphingolipids and the N-glycome in Lupus Nephritis and Renal Mesangial Cell Function

(0899–0933) SLE – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 1199

Association of Dipeptidyl Peptidase-4 Inhibitor Use for Type 2 Diabetes and Incidence of OA in Taiwan

(1183–1199) Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1448

Association of Disease Activity and Anti-Double Stranded DNA Antibodies Titers with Echocardiographic Parameters in Systemic Lupus Erythematosus Patients

(1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II

9:00AM-11:00AM: Abstract Number: 1488

Association of Glucocorticoid Use with Patient-Reported Outcomes Among Persons with Systemic Lupus Erythematosus

(1488–1512) SLE – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1019

Association of Historical Redlining and Present-Day Neighborhood Inequities with Missed Outpatient Appointments Among Individuals with Rheumatic Conditions

(1013–1032) Healthcare Disparities in Rheumatology Poster II: Socioeconomic Determinants

9:00AM-11:00AM: Abstract Number: 0975

Association of HLA-DRB1 Alleles with Ischemic Events and Mortality in a Multi-ethnic Community-living Population

(0965–0992) Epidemiology & Public Health Poster II

9:00AM-11:00AM: Abstract Number: 1196

Association of Long-Term Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) with Worsening Symptoms and Structural Changes of Knee Osteoarthritis: An Individual Patient Data Meta-Analysis of Cohort Studies

(1183–1199) Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1359

Association of Menstrual Cycles and Disease Flare Activity in Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis

(1345–1364) Reproductive Issues in Rheumatic Disorders Poster II

9:00AM-11:00AM: Abstract Number: 1461

Association of Serum Analytes with SLE Cognitive Impairment Phenotypes Formed by Machine Learning: MMP-9, S100A8/A9, IL-6, IL-10, and NGAL

(1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II

«Previous Page
1
…
3
4
5
6
7
…
57
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].